CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

xl999

Small moleculeexperimental

Clinical trial activity

10 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2004 (NCT00104117)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Mol. weight
445.54 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • xl999
  • xl999
  • xl-999

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01945164N/AApr 1, 2010University of Texas, San Antonio
NCT00955084Phase 1Aug 1, 2008Symphony Capital
NCT00491699Phase 1Aug 1, 2007Exelixis, Symphony Capital
NCT00322673Phase 2May 1, 2006Exelixis, Symphony Capital
NCT00304590Phase 2Feb 1, 2006Exelixis, Symphony Capital
NCT00277290Phase 2Jan 1, 2006Exelixis, Symphony Capital
NCT00277329Phase 2Dec 1, 2005Exelixis, Symphony Capital
NCT00277316Phase 2Dec 1, 2005Exelixis, Symphony Capital
NCT00277303Phase 2Dec 1, 2005Exelixis, Symphony Capital
NCT00104117Phase 1Nov 1, 2004Exelixis, Symphony Capital
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Symphony CapitalFor profit9922004
ExelixisFor profit8022004
University of Texas, San AntonioAcademic/Hospital1112010
3 organizations
Page 1 / 1